相关实验视频

Updated: May 5, 2026

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

一个ROS响应的多功能向前药菌细胞,用于动脉样硬化治疗

Zishuo Zhou¹, Yaxue Liu¹, Pei Xie¹

¹Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.

International journal of pharmaceutics

|June 20, 2024

概括

一种新型的simvastatin (SV) micelle,SPCPV,通过释放SV作为反应性氧物种 (ROS) 的反应来向动脉样硬化斑块. 这种向治疗对治疗早期动脉样硬化有很高的稳定性和安全性的承诺.

科学领域:

心血管研究研究心血管研究
纳米医学是一种纳米医学.
药理学药理学是指药理学的学科.

背景情况:

动脉样硬化是一种复杂的心血管疾病,需要早期,有针对性的干预措施.
目前的治疗方法缺乏精度,需要先进的药物输送系统.
向VCAM-1提供了一种针对动脉样硬化病变局部治疗的策略.

研究的目的:

开发一种含有simvastatin (SV) 的前药物微粒 (SPCPV) 用于向性动脉样硬化治疗.
调查SPCPV在动脉样硬化病变中过度表达的VCAM-1的向能力.
评估SPCPV在治疗早期动脉样硬化的体外和体内疗效.

主要方法:

合成的SPCPV小胞体包含过酸乙键,用于药物释放.
实验室研究评估了SPCPV在炎症细胞和正常细胞中的吸收,以及它对ROS,炎症,泡细胞形成和胆固醇流量的影响.
在动脉样硬化大鼠的体内研究评估了SPCPV对血管壁厚度和LDL水平的影响.

主要成果:

SPCPV显示在炎症细胞中有针对性的吸收,并通过细胞内ROS触发了simvastatin释放.
在体外,SPCPV有效地降低了ROS,表现出抗炎性质,抑制了泡细胞的形成,并促进了胆固醇排泄.
在体内,SPCPV显著降低了动脉样硬化大鼠的血管壁厚度和LDL水平.

结论:

SPCPV代表了针对动脉样硬化斑块的稳定和安全的药物输送策略.
这种集成simvastatin的有针对性的方法显示了早期动脉样硬化症的显著治疗潜力.
SPCPV系统为心血管疾病治疗提供了一个有前途的精准医学策略.

关键词:

动脉样硬化是一种动脉样硬化.循环德克斯特林 (Cyclodextrins) 是一种循环德克斯特林.它们是前药物.这就是ROSOS ROS.西姆瓦斯塔丁是一种

更多相关视频

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

Published on: December 23, 2016

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

相关概念视频

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...